(-0.07%) 5 474.50 points
(-0.10%) 38 778 points
(-0.04%) 19 914 points
(0.22%) $80.51
(1.33%) $2.83
(0.23%) $2 334.30
(-0.17%) $29.34
(-0.20%) $969.00
(0.02%) $0.932
(-0.15%) $10.64
(0.07%) $0.788
(-1.86%) $86.81
Live Chart Being Loaded With Signals
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation...
Stats | |
---|---|
Šios dienos apimtis | 6.83M |
Vidutinė apimtis | 1.87M |
Rinkos kapitalizacija | 85.83M |
EPS | $-0.270 ( Q1 | 2024-05-09 ) |
Kita pelno data | ( $0 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.220 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00100 (0.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-11 | Duraibabu Prathyusha | Sell | 892 | Common Stock |
2024-06-04 | Smith Karen L. | Buy | 25 000 | Common Stock |
2024-06-04 | Smith Karen L. | Buy | 50 000 | Stock Option (Right to Buy) |
2024-06-04 | Parker H Stewart | Buy | 25 000 | Common Stock |
2024-06-04 | Parker H Stewart | Buy | 50 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
5.30 |
Last 100 transactions |
Buy: 6 286 075 | Sell: 6 347 308 |
Tūris Koreliacija
Sangamo Therapeutics Inc Koreliacija
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
DOCU | -0.801 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Sangamo Therapeutics Inc Koreliacija - Valiuta/Žaliavos
Sangamo Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $176.23M |
Bruto pelnas: | $154.04M (87.41 %) |
EPS: | $-1.480 |
FY | 2023 |
Pajamos: | $176.23M |
Bruto pelnas: | $154.04M (87.41 %) |
EPS: | $-1.480 |
FY | 2022 |
Pajamos: | $111.30M |
Bruto pelnas: | $99.19M (89.12 %) |
EPS: | $-1.250 |
FY | 2021 |
Pajamos: | $110.70M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.230 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.